United Therapeutics Corporation (UTHR)

US — Healthcare Sector
Peers: BMRN  PCVX  LQDA  LEGN  TECH  NBIX  ALKS  JAZZ 

Automate Your Wheel Strategy on UTHR

With Tiblio's Option Bot, you can configure your own wheel strategy including UTHR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol UTHR
  • Rev/Share 68.2439
  • Book/Share 159.0599
  • PB 2.4997
  • Debt/Equity 0.0
  • CurrentRatio 7.2603
  • ROIC 0.1507

 

  • MktCap 17981976880.0
  • FreeCF/Share 23.7472
  • PFCF 16.7899
  • PE 14.4366
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 0.1873

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 5
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation UTHR Cantor Fitzgerald -- Overweight -- $405 June 2, 2025
Downgrade UTHR Wells Fargo Overweight Equal Weight -- -- April 25, 2025
Upgrade UTHR BofA Securities Underperform Neutral -- $314 April 21, 2025

News

United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
UTHR
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative

UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates.

Read More
image for news United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
United Therapeutics (UTHR) Surpasses Q4 Earnings and Revenue Estimates
UTHR
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive

United Therapeutics (UTHR) came out with quarterly earnings of $6.19 per share, beating the Zacks Consensus Estimate of $6.10 per share. This compares to earnings of $4.36 per share a year ago.

Read More
image for news United Therapeutics (UTHR) Surpasses Q4 Earnings and Revenue Estimates
United Therapeutics: A Unique Business With High Margins And Expansion Potential
UTHR
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakthroughs, and international market expansion.

Read More
image for news United Therapeutics: A Unique Business With High Margins And Expansion Potential

About United Therapeutics Corporation (UTHR)

  • IPO Date 1999-06-17
  • Website https://www.unither.com
  • Industry Biotechnology
  • CEO Martine A. Rothblatt
  • Employees 1305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.